• Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring allogeneic hematopoietic stem cell transplantation as determined by the researchers;

• Age 3-65 years old;

• Weight 10Kg-100Kg;

• Eastern Cooperative Oncology Group (ECOG) score ≤3;

• No major organ injury (ECG ejection fraction \>45%; bilirubin \< 2 times the upper limit of normal value; AST and ALT \< 3 times the upper limit of normal value; serum creatinine \< 2 times the upper limit of normal value);

• No severe infection;

• Subjects voluntarily participated in this clinical trial and signed the informed consent.